-
Nature's universal CAR-T announces preclinical data targeting two hematological malignancies
Time of Update: 2022-05-29
▲ The process of the mouse experiment, picture source: Nature communications At the same time, the published preclinical data also showed that UCART123 effectively eliminated AML without significant impact on normal hematopoietic progenitor cells; it proved that UCART123 has strong anti-BPDCN activity; Human evaluation for the treatment of r/r AML (adult relapsed or refractory acute myeloid leukemia) is also currently in Phase 1 clinical trials of the AMELI-01 study .
-
Gastroenterology Chongqing University Tang Liling and other teams discover potential therapeutic targets for intrahepatic cholangiocarcinoma
Time of Update: 2022-05-29
Calvisi of University of Regensburg published a joint communication online in Gastroenterology (IF=23) entitled "β-Catenin sustains and is required for YES-associated protein oncogenic activity in cholangiocarcinoma”, which found that TEAD factors are required for YAP-dependent iCCA development .
In conclusion, this study found that YAP induces cholangiocarcinogenesis through TEAD-dependent transcriptional activation and interaction with β-Catenin .
-
The gastric cancer treatment guidelines are updated, and new changes in surgery and neoadjuvant therapy are here!
Time of Update: 2022-05-28
Picture from the conference PPT The 2021 NEO AEGIES study compared the efficacy and safety of the intensive three-drug perioperative chemotherapy mode and the preoperative CROSS regimen neoadjuvant concurrent chemoradiotherapy for adenocarcinoma of the esophagogastric junction.
-
Pancreatic cancer double immune + radiotherapy phase 2 trial achieved good results
Time of Update: 2022-05-28
Lancet Oncol: Quality of life analysis from the CLEAR study showed that patients with advanced renal cell carcinoma who received lenvatinib plus pembrolizumab had similar or better quality of life scores than sunitinib, especially in the time to final disease progression .
-
[Nature sub-issue] Combining two clinical cancer drugs, "two-pronged" treatment of specific colorectal cancer
Time of Update: 2022-05-28
Author: Ashley Introduction: A recent study of colon cancer with specific partial mutations of the PIK3CA gene found that the combination drug Apelisib and Tazemostat was effective in targeting two signaling pathways involved in these mutations .
-
Case Sharing: Treatment and thinking of a case of stage IVA thymoma
Time of Update: 2022-05-28
Treatment decision-making The comprehensive treatment principles for Masaoka-Koga stage III-IVA thymoma, the 2021 edition of the "Chinese Guidelines for Clinical Diagnosis and Treatment of Thymic Epithelial Tumors" has made the following specifications [4]: (1) For patients with resectable lesions, direct surgical treatment is recommended; although Lack of high-level evidence, most data support postoperative adjuvant radiotherapy .
-
Dr. Live is based on data, based on reality: Professor Cui Chuanliang interprets CSCO kidney cancer guidelines
Time of Update: 2022-05-28
The results of the KEYNOTE-052 study showed that pembrolizumab was used for the first-line treatment of patients with metastatic bladder cancer who were intolerant to platinum, and the ORR of the patients was 29%, and the median OS was 11.
-
Express delivery enhances the durability of therapy, and differentiated CAR-T therapy is recognized by the FDA as an advanced therapy for regenerative medicine
Time of Update: 2022-05-28
▎WuXi AppTec Content Team Editor A few days ago, Autolus Therapeutics (hereinafter referred to as Autolus) announced that its investigational therapy obecabatagene autoleucel (obe-cel) has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the US FDA .
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus' CAR T cell therapy, obe-cel, for the treatment of adult B-ALL.
-
Breaking through the limitations of stem cell therapy and taking stock of the multiple application directions of CD117 targets
Time of Update: 2022-05-28
>>>>CD117 Gene therapyIn June 2021, Jasper Therapeutics and Aruvant announced a research collaboration to evaluate JSP191 (Jasper's anti-CD117 monoclonal antibody) and Aruvant's lentiviral gene therapy ARU for SCD (sickle cell disease) - Use of 1801 as a targeted, non-toxic modulator .
-
How to identify benign and malignant thyroid nodules?
Time of Update: 2022-05-28
In recent years, the incidence of thyroid cancer has increased rapidly worldwide.
Thyroid cancer in China will continue to increase at a rate of 20% every year .
Recently, the full text of the "Guidelines for the Diagnosis and Treatment of Thyroid Cancer (2022 Edition)" was released.
-
After developing a deadly cancer, their cancer cells disappeared on their own…
Time of Update: 2022-05-28
For those high-risk patients with highly active MYCN gene, this study provides a new understanding of the balance of cysteine intake, production and consumption, and also provides more researchers with a new way to initiate the self-destruction process of cancer cells ideas .
-
Interview with Nie Guangjun of the National Center for Nanoscience: Genetic engineering of gut bacteria makes oral cancer vaccine possible
Time of Update: 2022-05-28
Written | Edited by Wang Cong | Typesetting by Wang Duoyu | Shui Chengwen On May 2, 2022, Nie Guangjun's team from the National Nanoscience Center published a paper in the journal Nature Biomedical Engineering, developing a genetically engineered bacteria by genetically engineering Escherichia coli source of outer membrane vesicle (OMV)-based oral tumor vaccines .
-
The results of the ORIENT-15 study were released, and the immunotherapy of esophageal cancer reached a new high!
Time of Update: 2022-05-28
*For medical professionals only, the ORIENT-15 study is a randomized, double-blind, international, multicenter, large-scale phase III trial comparing sintilimab combined with chemotherapy versus chemotherapy alone in first-line treatment of locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma.
-
Express blood test for cancer detection, early colorectal cancer screening test launched, with a sensitivity of 91%
Time of Update: 2022-05-28
▎WuXi AppTec Content Team Editors Today, Guardant Health announced the launch of the Shield blood test to detect early signs of colorectal cancer in adults at average risk .
-
Dr. Live's immune remodeling pattern, targeted and precise endurance: Professor Sheng Xinan talks about the current status of diagnosis and treatment of kidney cancer and the progress of treatment
Time of Update: 2022-05-28
In recent years, there have been many large-scale clinical studies of immune combined with targeted drugs for first-line treatment of advanced renal cancer, which has affected the pattern of renal cancer treatment .
-
Professor Song Yuqin welcomes the hope of cure for 200 patients with Benoda®, and jointly hopes for the 2-year OS survival rate
Time of Update: 2022-05-28
Professor Song Yuqin's Ruiki Orenza injection is currently marketed in China for r/r LBCL in adult patients after second-line or above systemic therapy, including DLBCL, high-grade B-cell lymphoma (HGBL) and follicular lymphoma (FL) Converted DLBCL et al .
-
Professor Yuan Ying: Rewrite the guideline recommendation for the phase II trial of nvolimab, MSI-H/dMMR detection helps "precise immunity"
Time of Update: 2022-05-28
Envolizumab is the world's first PD-L1 monoclonal antibody in subcutaneous injection form, and will be approved by China's National Medical Products Administration (NMPA) in 2021 for unresectable or metastatic MSI-H/dMMR adult patients with advanced solid tumors The "2022 CSCO Colorectal Diagnosis and Treatment Guidelines" also included it into the second-line and third-line regimens of the palliative care group.
-
CSCO Pancreatic Cancer Guidelines Medical Treatment Update Highlights 2022 CSCO Guidelines Meeting
Time of Update: 2022-05-27
SWOG S1505: mFOLFIRINOX vs gemcitabine/nab-paclitaxel (Gem/nabP) perioperative treatment of resectable pancreatic ductal adenocarcinoma (PDA) study results (randomized phase II clinical study), the primary endpoint is 2-Year Overall Survival (OS) Rate (2020 ASCO): Patients with newly diagnosed resectable pancreatic cancer received mFOLFIRINOX or gemcitabine/nab-paclitaxel 12 weeks before and 12 weeks after surgery; The 2-year OS rates in the protein paclitaxel group were 43.
-
Express reduces the risk of death in patients with biliary tract cancer by 20%, and the blockbuster PD-L1 inhibitor combination has been granted priority review by the FDA
Time of Update: 2022-05-27
” Reference: [1] Imfinzi Plus Chemotherapy Granted Priority Review in the US for Patients With Locally Advanced or Metastatic Biliary Tract Cancer Based on TOPAZ-1 Phase III Trial.
-
[Wednesday reading literature] Big coffee commented on Chen Suning/Xue Song: AML with t(8;21) and KIT mutations relapsed after allo-HSCT and treated with avatinib for rapid remission
Time of Update: 2022-05-27
In recent years, great progress has been made in treatment, including molecular targeted therapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT), but the long-term survival rate of AML patients is still only about 25% .
